EMEA-002862-PIP01-20-M02
Key facts
| Invented name |
Vaxzevria (previously COVID-19 Vaccine AstraZeneca)
|
| Active substance |
COVID-19 vaccine (ChAdOx1-S [recombinant]) (AZD1222)
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0559/2021
|
| PIP number |
EMEA-002862-PIP01-20-M02
|
| Pharmaceutical form(s) |
Suspension for injection
|
| Condition(s) / indication(s) |
Prevention of Coronavirus disease 2019 (COVID-19)
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
AstraZeneca AB
Tel. +46 855324400 E-mail: paediatrics@astrazeneca.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|